MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1

Q1 2016 13F Holders as of 31 Mar 2016

Type / Class
Debt / NOTE 4.500% 7/1
Market price (% of par)
149.51%
Total 13F principal
$115,416,000
Principal change
+$16,416,000
Total reported market value
$173,610,000
Number of holders
15
Value change
+$24,942,508
Number of buys
5
Number of sells
6

Institutional Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q1 2016

As of 31 Mar 2016, MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 was held by 15 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $115,416,000 in principal (par value) of the bond. The largest 10 bondholders included CITADEL ADVISORS LLC, Polygon Management Ltd., LAZARD ASSET MANAGEMENT LLC, SILVERBACK ASSET MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, ARISTEIA CAPITAL LLC, JPMORGAN CHASE & CO, Polar Capital LLP, PUTNAM INVESTMENTS LLC, and TANG CAPITAL MANAGEMENT LLC. This page lists 15 institutional bondholders reporting positions for the Q1 2016 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.